BC Extra | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

Two companies have chronic hepatitis D virus therapies in Phase III trials with designs that could support accelerated approval, based on an FDA draft guidance released Friday. There are no approved drugs for HDV, though...
BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Week In Review | Oct 26, 2018
Financial News

Eiger prices $43.4M follow-on

Orphan disease company Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) raised $43.5 million through the sale of 4.3 million shares at $10.35 in a follow-on underwritten by BTIG. The price is a 13% discount to the company's close...
BC Extra | Sep 4, 2018
Company News

Eiger to seek FDA approval of progeria therapy

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) intends to submit an NDA to FDA next year for lonafarnib to treat Hutchinson-Gilford progeria syndrome, an ultra-rare premature aging disease. The company said the NDA will be based on existing...
BC Week In Review | Jun 29, 2018
Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering...
BC Extra | Jun 28, 2018
Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by...
BC Innovations | May 9, 2018
Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggest farnesyl transferase inhibitors plus the oncolytic alphavirus M1 could help treat colorectal and pancreatic cancers. In a human colorectal cancer cell line treated with alphavirus M1, co-treatment...
BC Week In Review | Feb 16, 2018
Clinical News

Kura reports additional Phase II data for tipifarnib in SCCHN

Kura Oncology Inc. (NASDAQ:KURA) reported updated data from six evaluable patients with v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the head and neck (SCCHN) in a Phase...
BC Week In Review | Feb 2, 2018
Financial News

Kura raises $59.1M in an at-the-market financing

Cancer company Kura Oncology Inc. (NASDAQ:KURA) raised $59.1 million on Jan. 24 through the sale of 3.1 million shares at $18.85 in an at-the-market financing underwritten by Cowen. Kura reported preliminary data in December from...
BC Week In Review | Jan 5, 2018
Clinical News

Kura reports Phase II data for tipifarnib in CMML

Kura Oncology Inc. (NASDAQ:KURA) reported preliminary data from nine evaluable patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that tipifarnib led to an overall response rate (ORR) of 33%,...
Items per page:
1 - 10 of 82